Drug research

REL-1017

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Esmethadone HCl; d-Methadone; esmethadone

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)NCT05081167	RLMD	Phase 3	Completed	2022-09-13Actual
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDNCT03051256	RLMD	Phase 2	Completed	2019-07-30Actual
Safety of REL-1017 for Major Depressive DisorderNCT04855760	RLMD	Phase 3	Completed	2023-07-27Actual
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04688164	RLMD	Phase 3	Completed	2022-11-01Actual

RLMDCompletedPrimary completion: 2022-09-13 · Actual

Trial details

RLMDCompletedPrimary completion: 2019-07-30 · Actual

Trial details

RLMDCompletedPrimary completion: 2023-07-27 · Actual

Trial details

RLMDCompletedPrimary completion: 2022-11-01 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.